Organisation paid for research Program year 2023 Source: CMS Open Payments

Altea Research

Neither a doctor nor a teaching hospital

Research payments

$202,183

50 payments

Through program year 2023, Altea Research is reported as receiving $202,183 in research payments, across 50 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$13,673	1
2022	Research	$6,852	3
2021	Research	$178,157	44
2020	Research	$1,750	1
2019	Research	$1,750	1

Breakdown

Who paid Research payments · program years 2019–2023

Corcept Therapeutics $117,816 27 payments
Merck Sharp & Dohme Corporation $57,464 4 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $19,278 2 payments
ACADIA Pharmaceuticals Inc $3,500 2 payments
Boehringer Ingelheim Canada Ltd.Ltee $2,878 13 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $752 1 payment
AbbVie, Inc. $495 1 payment

Studies the money was for Research payments · program years 2019–2023

Cort118335-877 $84,347 20 payments
A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression $57,429 3 payments
Cort118335-876 $33,469 7 payments
PoCC study in patients with PTSD $20,030 3 payments
Acp-103-042 $3,500 2 payments
Connex-2 $2,878 13 payments
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features $495 1 payment
A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer s Disease Dementia $35 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.